Nora Pencheva
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
Journal: Cancer research communications
Published: September 12, 2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.
Journal: Journal for immunotherapy of cancer
Published: March 24, 2025
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies.
Journal: Frontiers in oncology
Published: December 19, 2024
Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.
Journal: International journal of molecular sciences
Published: May 30, 2022
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Journal: Cancer research
Published: February 05, 2020
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Journal: JCI insight
Published: February 25, 2019
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Journal: Cell
Published: October 06, 2017
Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.
Journal: Cell reports
Published: January 27, 2017
Control of metastatic progression by microRNA regulatory networks.
Journal: Nature cell biology
Published: June 04, 2013
Last Updated: 09/26/2026